Sarah Aebersold Sells 5,771 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 5,771 shares of the company’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total transaction of $130,770.86. Following the transaction, the insider now directly owns 80,094 shares of the company’s stock, valued at approximately $1,814,930.04. This represents a 6.72 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Sarah Aebersold also recently made the following trade(s):

• On Monday, March 17th, Sarah Aebersold sold 2,695 shares of BioLife Solutions stock. The shares were sold at an average price of $25.44, for a total value of $68,560.80.
• On Friday, March 14th, Sarah Aebersold sold 5,632 shares of BioLife Solutions stock. The stock was sold at an average price of $24.96, for a total value of $140,574.72.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The shares were sold at an average price of $25.00, for a total value of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $6,484.80.

BioLife Solutions Trading Down 5.6 %

Shares of BLFS opened at $22.44 on Friday. BioLife Solutions, Inc. has a one year low of $14.84 and a one year high of $29.55. The stock has a 50-day moving average price of $26.00 and a 200 day moving average price of $25.51. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The company has a market capitalization of $1.05 billion, a P/E ratio of -21.17 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The business had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. During the same quarter in the previous year, the firm earned ($0.21) earnings per share. Sell-side analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BLFS has been the subject of several research reports. StockNews.com downgraded shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research note on Monday. Northland Securities increased their price target on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a report on Wednesday, January 8th. Benchmark restated a “buy” rating and set a $30.00 price objective on shares of BioLife Solutions in a research note on Thursday, December 19th. HC Wainwright increased their target price on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. Finally, KeyCorp boosted their price target on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $29.86.

Hedge Funds Weigh In On BioLife Solutions

Large investors have recently modified their holdings of the stock. D.A. Davidson & CO. raised its stake in BioLife Solutions by 1.3% during the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock valued at $1,069,000 after buying an additional 519 shares in the last quarter. Stifel Financial Corp raised its position in shares of BioLife Solutions by 5.4% during the 3rd quarter. Stifel Financial Corp now owns 12,988 shares of the medical equipment provider’s stock valued at $325,000 after acquiring an additional 670 shares in the last quarter. 1620 Investment Advisors Inc. raised its position in shares of BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after acquiring an additional 675 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in BioLife Solutions by 27.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider’s stock worth $117,000 after purchasing an additional 950 shares during the last quarter. Finally, Steward Partners Investment Advisory LLC acquired a new position in BioLife Solutions in the fourth quarter worth $26,000. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.